T cells are an important part of the immune system, playing a critical role in the response to infected, foreign or altered cells.
Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.
Team
Insights
Purpose
Commitment
Our People
Companies
News & insights
Information
Legal
News & insights
Information
Legal
Location: United Kingdom, England, Cambridge
Total raised: $59.63M
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| 18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.11.2023 | Series A | $59.63M | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 19.03.2024 | The World’s Most Innovative Companies of 2024 | - | fprimecapi... |
| 21.11.2023 | Parkwalk supports ‘Founders at the University of Cambridge’ ... | Along with 100 experts from Graphcore, Arm, Google and Stripe, we are proud to support the Founders ... | parkwalkad... |
| 16.11.2023 | T-Therapeutics Raises £48M in Series A Financing | T-Therapeutics, a Cambridge, UK-based biotechnology company developing TCR therapeutics, raised $48M... | finsmes.co... |
| 15.11.2023 | T-Therapeutics raises £48 million Series A for development o... | - | fprimecapi... |
| - | T-Therapeutics | “Home - T-Therapeutics” | fastfounde... |